TCM
LPCN icon

Tang Capital Management’s Lipocine LPCN Stock Holding History

Tang Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,294
Closed -$790K – 11
2016
Q2 		$790K Buy
15,294
+9,412
+160% +$1.46M 0.35% 10
2016
Q1 		$1.01M Buy
+5,882
New +$1M 0.46% 12

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Tang Capital Management's LPCN Position: Q3 2016 in Review

Tang Capital Management sold out of Lipocine (LPCN) in Q3 2016, closing a stake of 15,294 shares — an estimated $790K sold.

Tang Capital Management first reported a position in LPCN in Q1 2016 and held it in 2 quarters. The position peaked at $1.01M in Q1 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q3 2016.

  • Tang Capital Management reported no remaining Lipocine position as of Q3 2016 after selling out during the quarter.
  • Tang Capital Management sold 15,294 Lipocine shares in Q3 2016, an estimated $790K.
  • Tang Capital Management first reported a position in Lipocine in Q1 2016 and held it in 2 quarters.
  • Tang Capital Management's Lipocine position peaked at $1.01M in Q1 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q3 2016.

Based on Tang Capital Management's 13F filing for Q3 2016, filed 15 Nov 2016.